Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963415 · ClinicalTrials.gov registry record · NA
Concurrent Aerobic Exercise and Virtual Reality Cognitive Training
A NA study of Preclinical Alzheimer's Disease, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02963415 is a NA study of Preclinical Alzheimer's Disease that has completed, run by University of Minnesota. The registered enrollment target is 39 participants, below the 966-participant average among 3 other Preclinical Alzheimer's Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02963415, a NA study of Preclinical Alzheimer's Disease, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will implement and test a unique Virtual Reality Cognitive Training (VRCT) combined with concurrent cycling on a recumbent stationary cycle, also known as exergame that seamlessly integrates specific cognitive tasks into a virtual environment and is synchronized with cycling to promote cognition.
Conditions Studied
Interventions
- BEHAVIORAL Exergame
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02963415
The ClinicalTrials.gov registry entry for NCT02963415 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 966-participant average among 3 other Preclinical Alzheimer's Disease trials with a reported enrollment target (96% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Preclinical Alzheimer's Disease appearing as the primary indexed condition, and to 1 intervention - of which Exergame is the first listed.
NCT02963415 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02963415 about?
NCT02963415 is a clinical study titled "Concurrent Aerobic Exercise and Virtual Reality Cognitive Training". The study will implement and test a unique Virtual Reality Cognitive Training (VRCT) combined with concurrent cycling on a recumbent stationary cycle, also known as exergame that seamlessly integrates specific cognitive tasks into a virtual environment and is synchronized with cycling to promote cog...
What is the current status of trial NCT02963415?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2019-03-01. Estimated completion is 2022-03-31.
What conditions does trial NCT02963415 study?
This clinical trial studies the following conditions: Preclinical Alzheimer's Disease.
What interventions are being tested in trial NCT02963415?
The interventions under investigation include: Exergame (BEHAVIORAL).
Who is sponsoring clinical trial NCT02963415?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02963415 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preclinical Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Alzheimer's Plasma Extension
ACTIVE NOT RECRUITING
-
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.